600713 南京医药
2024/09 - 九个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入40,938,1810.97%53,589,66550,221,56445,123,19539,817,364
减:营业总成本40,123,0960.79%52,645,43949,186,22344,249,16039,093,743
    其中:营业成本38,414,5400.87%50,276,36246,962,43042,185,98537,286,150
               财务费用400,554-0.11%534,751435,170441,844359,591
               资产减值损失(2,124)-46.13%(6,248)(6,771)(8,618)(14,994)
公允价值变动收益------------
投资收益3,097-64.44%8,581(48,645)(87,739)(92,916)
    其中:对联营企业和合营企业的投资收益1,066-82.96%6,062(519)(2,900)(17,206)
营业利润771,6082.24%1,007,443934,323845,713676,261
利润总额762,5544.15%978,068906,012838,866677,799
减:所得税费用198,748-0.23%265,259190,092228,314207,761
净利润563,8075.79%712,809715,920610,552470,038
减:非控股权益121,92431.57%134,983120,252105,36993,625
股东净利润441,8820.36%577,826595,668505,183376,413

市场价值指针
每股收益 (元) *0.3400.00%0.4450.4750.4850.361
每股派息 (元) *----0.1600.1400.1200.110
每股净资产 (元) *5.1276.76%4.9124.5794.4224.087
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容